While the semaglutide CVOTs did not show an increased incidence of hospitalization for HF compared to placebo (101), in earlier smaller studies with liraglutide in patients with HF with reduced left ventricular ejection fraction, the GLP-1RA was associated with increased incidence of serious cardiac events (rhythm disorders, worsening of HF) (102, 103)
Because of the potential for these chemicals to bind to oestrogen receptors, it was hypothesised that they could potentially stimulate the growth of ER+ breast cancers 31, 32
Injectable agents, such as glucagon-like peptide-1 receptor agonists (GLP-1 RAs), and insulin and insulin analogues (rapid-acting, intermediate, or long-acting forms), may also be considered as an add-on to MET, or patients can be switched to insulin
Open communication about your treatment experience enables appropriate adjustments and helps identify any concerning developments early
***The use of any trademarks, tradenames or service marks is solely for product identification and/or informational purposes